Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3807-3814

  Lan, Ya Chun ^a   Chang, Chia Ling ^a   Sung, Ming Ta ^b   Yin, Pen Hui ^b   Hsu, Chia Chi ^a   Wang, Kuo Chung ^b   Lee, Hsin Chen ^a   Tseng, Ling Ming ^b   Chi, Chin Wen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Breast cancer; Endoplasmic reticulum stress; MCF 7; MDA MB 231 cells; MTOR; REDD1; Zoledronic acid

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; DEVELOPMENT AND DNA DAMAGE RESPONSE 1 PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN; INITIATION FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN KINASE R; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR CELL LINE; WESTERN BLOTTING;

BREAST CANCER; ENDOPLASMIC RETICULUM STRESS; MCF-7; MDA-MB-231 CELLS; MTOR; REDD1; ZOLEDRONIC ACID;

BASE SEQUENCE; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CELL DIVISION; DIPHOSPHONATES; DNA PRIMERS; ENDOPLASMIC RETICULUM; FEMALE; HUMANS; IMIDAZOLES; MCF-7 CELLS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84884992945     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Nguyen DX, Bos PD and Massague J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284, 2009.
2. Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593, 2002.
3. Winter MC, Holen I and Coleman RE: Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453-475, 2008.
4. Holen I and Coleman RE: Antitumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 12: 214, 2010.
5. Brown HK and Holen I: Antitumour effects of bisphosphonates-What have we learned from in vivo models? Curr Cancer Drug Targets 9: 807-823, 2009.
6. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK and Lewiecki EM: Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 126: 13-20, 2013.
7. Roux C and Dougados M: Treatment of patients with Paget's disease of bone. Drugs 58: 823-830, 1999.
8. Coleman RE: Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176, 2001.
9. Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 359: 2018-2026, 2002.
10. Gnant M and Clezardin P: Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. Cancer Treat Rev 38: 407-415, 2012.
11. Fromigue O, Lagneaux L and Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221, 2000.
12. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000.
13. Verdijk R, Franke HR, Wolbers F and Vermes I: Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 246: 308-312, 2007.
14. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM and Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
15. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002.
16. Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, Maekawa T, Kubo T and Fushiki S: Combined effects of a thirdgeneration bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 96: 255-261, 2007.
17. Clyburn RD, Reid P, Evans CA, Lefley DV and Holen I: Increased antitumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: Supporting the benefits of combination therapy. Cancer Chemother Pharmacol 65: 969-978, 2010.
18. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ and Thorpe H: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br J Cancer 102: 1099-1105, 2010.
19. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR and Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1978, 2003.
20. Hay N: The AKT-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183, 2005.
21. DeYoung MP, Horak P, Sofer A, Sgroi D and Ellisen LW: Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22: 239-251, 2008.
22. Sofer A, Lei K, Johannessen CM and Ellisen LW: Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol 25: 5834-5845, 2005.
23. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW and Kaelin WG Jr.: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18: 2893-2904, 2004.
24. Lin L, Stringfield TM, Shi X and Chen Y: Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors ELK-1 and CCAAT/enhancer-binding protein. Biochem J 392: 93-102, 2005.
25. Chen JC, Wu ML, Huang KC and Lin WW: HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc Res 80: 138-150, 2008.
26. Schmitz A and Herzog V: Endoplasmic reticulum-associated degradation: Exceptions to the rule. Eur J Cell Biol 83: 501-509, 2004.
27. Rutkowski DT and Kaufman RJ: A trip to the ER: coping with stress. Trends Cell Biol 14: 20-28, 2004.
28. Schroder M and Kaufman RJ: ER stress and the unfolded protein response. Mutation Res 569: 29-63, 2005.
29. Rao RV, Peel A, Logvinova A, del Rio G, Hermel E, Yokota T, Goldsmith PC, Ellerby LM, Ellerby HM and Bredesen DE: Coupling endoplasmic reticulum stress to the cell death program: Role of the ER chaperone GRP78. FEBS Lett 514: 122-128, 2002.
30. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, Harding H, Novoa I, Varia M, Raleigh J, Scheuner D, Kaufman RJ, Bell J, Ron D, Wouters BG and Koumenis C: ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 24: 3470-3481, 2005.
31. Wang Z, Malone MH, Thomenius MJ, Zhong F, Xu F and Distelhorst CW: Dexamethasone-induced gene 2 (DIG2) is a novel pro-survival stress gene induced rapidly by diverse apoptotic signals. J Biol Chem 278: 27053-27058, 2003.
32. Protiva P, Hopkins ME, Baggett S, Yang H, Lipkin M, Holt PR, Kennelly EJ and Bernard WI: Growth inhibition of colon cancer cells by polyisoprenylated benzophenones is associated with induction of the endoplasmic reticulum response. Int J Cancer 123: 687-694, 2008.
33. Hasmim M, Bieler G and Ruegg C: Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 5: 166-173, 2007.
34. Madrid LV, Mayo MW, Reuther JY and Baldwin AS Jr.: AKT stimulates the transactivation potential of the RELA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 276: 18934-18940, 2001.
35. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE and Reusch JE: AKT/protein kinase B upregulates BCL-2 expression through cAMP-response elementbinding protein. J Biol Chem 275: 10761-10766, 2000.
36. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, Moshel Y, Elbaz S, Budanov A, Chajut A, Kalinski H, Kamer I, Rozen A, Mor O, Keshet E, Leshkowitz D, Einat P, Skaliter R and Feinstein E: Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 22: 2283-2293, 2002.
37. Espinoza I, Liu H, Busby R and Lupu R: CCN1, a candidate target for zoledronic acid treatment in breast cancer. Mol Cancer Ther 10: 732-741, 2011.
38. Tsai MS, Hornby AE, Lakins J and Lupu R: Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 60: 5603-5607, 2000.
39. Whitney ML, Jefferson LS and Kimball SR: ATF4 is necessary and sufficient for ER stress-induced up-regulation of REDD1 expression. Biochem Biophys Res Commun 379: 451-455, 2009.
40. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A and Bundred N: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann Oncol 24: 398-405, 2013.
41. Aft RL, Naughton M, Trinkaus K and Weilbaecher K: Effect of (neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br J Cancer 107: 7-11, 2012.